Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05GBH
|
||||
| Former ID |
DIB005848
|
||||
| Drug Name |
F4co vaccine
|
||||
| Synonyms |
F4co vaccine (AIDS/HIV infection)
|
||||
| Drug Type |
Vaccine
|
||||
| Company |
GlaxoSmithKline plc
|
||||
| Target and Pathway | |||||
| Target(s) | HIV p17 matrix protein | Target Info | [550167] | ||
| HIV reverse transcriptase | Target Info | [550167] | |||
| Negative factor | Target Info | [550167] | |||
| HIV p24 capsid protein | Target Info | [550167] | |||
| Reactome | Uncoating of the HIV Virion | ||||
| Budding and maturation of HIV virion | |||||
| Integration of provirus | |||||
| Early Phase of HIV Life Cycle | |||||
| Minus-strand DNA synthesis | |||||
| Plus-strand DNA synthesis | |||||
| 2-LTR circle formation | |||||
| Binding and entry of HIV virion | |||||
| Membrane binding and targetting of GAG proteins | |||||
| Assembly Of The HIV Virion | |||||
| Integration of viral DNA into host genomic DNA | |||||
| Autointegration results in viral DNA circles | |||||
| APOBEC3G mediated resistance to HIV-1 infection | |||||
| Vpr-mediated nuclear import of PICs | |||||
| WikiPathways | Host Interactions of HIV factors | ||||
| HIV Life Cycle | |||||
| References | |||||
| Ref 523204 | ClinicalTrials.gov (NCT01218113) Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naive HIV-1 Infected Persons. U.S. National Institutes of Health. | ||||
| Ref 548656 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027409) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.